A Chinese court found GlaxoSmithKline's local subsidiary guilty of bribery and fined the company nearly $500 million, capping a scandal that has shaken China's pharmaceutical industry.
Chinese authorities accused GSK of bribing hospitals and doctors, channeling illicit kickbacks through travel agencies and pharmaceutical industry associations — a scheme that brought the company higher drug prices and illegal revenue of more than $150 million between 2009 and 2012.